In chronic viral hepatitis, autoimmune hepatitis, and some chronic cholestatic liver diseases, T-lymphocytes serve as effector cells of the immunostimulatory processes. Cellular interactions of immune cells with extracellular matrix (ECM) components are regulated primarily via the f1 subfamily of integrin receptors. The target epitope of several such integrin receptors is the Arg-GlyAsp (RGD) sequence, a cell adhesion motif shared by several matrix-associated adhesive glycoproteins. We review the use of synthetic nonpeptidic analogues of RGD and of soluble receptor of tumor necrosis factor (TNF)-a in the prevention of immune-mediated, concanavalin A-induced liver damage in mice and of RGD analogues in inhibiting the development of liver cirrhosis in rats. The concanavalin A-induced elevation of serum transaminases and TNF-a, and the infiltration of liver tissue by inflammatory cells, were inhibited by pretreatment of the mice with the synthetic RGD mimetics and soluble TNF receptor. In rats, the progression of thioacetamide-induced liver cirrhosis was markedly inhibited by the coadministration of the RGD mimetic SF-6,5. The compounds described here may be examined therapeutically for pathological conditions in the liver, manifested as necroinflammation, cholestasis and fibrosis.
In several liver diseases, including chronic viral hepatitis, autoimmune chronic active hepatitis, and cholestatic liver diseases such as primary biliary cirrhosis and primary sclerosing cholangitis, T-lymphocytes serve as effector cells of the immunostimulatory processes. The inflammatory cell infiltrate is thought to contribute to liver injury either as a primary event, as in autoimmune hepatitis and primary biliary cirrhosis, or as a secondary response to another process such as chronic viral infection. In response to acute injury, T-cell activation results in production of cytokines such as tumor necrosis factor (TINF)-ad and IL (interleukin)-2, which maintain and augment the level of the inflammatory process and may induce acute toxicity. The accumulation of mononuclear cells at the site of injury depends in part on their ability to penetrate the sinusoidal endothelial cells and their adhesion to the extracellular matrix in the space of Disse. Both these processes are mediated by integrins, a family of cell surface adhesion receptors. Several matrix and plasma-associated glycoproteins such as fibronectin (FN) are recognized by integrins via the Arg-Gly-Asp (RGD) cell adhesion epitope.
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In this paper, we will review the use of synthetic analogues of the extracellular matrix-associated epitope RGD and soluble receptor of TNF in the prevention of immunemediated hepatitis, and of RGD mimetics in inhibiting hepatic fibrosis in experimental models of acute and chronic liver injury.
THE EXTRACELLULAR MATRIX-ASSOCIATED EPITOPE
Arg-Gly-Asp (RGD) IN CELL ADHESION Cellular interactions of immune cells with ECM components are regulated primarily by a family of transmembrane heterodimeric cell surface adhesion receptors of the integrin family [1] [2] [3] [4] . Each integrin is composed of a noncovalently associated a and 3 subunit. The P1 subfamily of integrins, also referred to as VLA (very late activation) receptors, are specific for various glycoprotein ligands of the ECM, such as FN, laminin, collagens, and vitronectin [4, 5] . Although the characterization and localization of integrin recognition sites on ECM glycoproteins has not been completely elucidated, the involvement of the Arg-Gly-Asp-(RGD) epitope in cell adhesion processes has been indicated [2, 6] . The RGD cell adhesion motif is also present in several matrix and plasma-associated glycoproteins such as FN, and is recognized by several integrins, including aIIcb133 on platelets, a3P1 (VLA-3), a5I1 (VLA-5), and most of the av-containing integrins [3] .
Upon cell activation, the RGD-containing sequence is recognized by several integrin receptors that mediate RGD-dependent matrix adhesion of cells. Interactions between immune cells and FN determine the subsequent activation and proliferation of the cells, and the secretion of cytokines such as TNFa, TGFB and fibroblast growth factor [8, 9] .
The use of RGD-containing peptides to prevent T cell-mediated inflammatory reactions has been suggested [7] . However, since these short RGD-containing peptides are highly susceptible to proteolysis, their preventive effect required pretreatment of the migrating cells with high concentrations of the RGD peptides, rather than in situ administration of the peptides [7] . Therefore, the clinical usage of such compounds to prevent damage due to T-cell-mediated inflammatory reactions in vivo is not practical.
NONPEPTIDIC MIMETICS OF RGD
We recently described the design and synthesis of novel nonpeptidic mimetics of RGD that contain guanidinium and carboxylate groups separated by an atom spacer, thus mimicking the functional groups of RGD [8] . Compound SF-6,5, is a nonpeptidic mimetic of RGD, which has an 11 atom spacer between the guanidinium and carboxylic groups that mimics the atomic spacing between the two groups in the RGD peptide. Compound NS-11 is a conformationally constrained RGD mimetic molecule, that was obtained by substituting a piperidine unit into a spacing chain [9] . The ring substitution in compound NS-1 1 restricts the conformational freedom of the carboxylate and guanidinium moieties in a constant spatial arrangement (Figure 1 ). These mimetics specifically inhibited (i) RGD-dependent platelet aggregation, and (ii) binding of T-lymphocytes and tumor cells to immobilized fibronectin and vitronectin. Also, we demonstrated that an RGD mimetic specifically inhibits actively induced, delayed-type hypersensitivity reactions and tumor cell colonization in mice [9, 10] , suggesting the involvement of RGD recognition in regulation of immune responses and migration of cells involved in pathological responses. The RGE (Arg-Gly-Glu acid) mimetic, SF-6,6, which has a 12-atom spacing chain between the two ionic functional groups (Figure 1) , and therefore lacks integrin specificity, was synthesized to be used as control. [11] . The induction of Con A hepatitis depends on the interaction between CD4+ T-helper cells and macrophages [11] , and as recently reported, on the production of cytokines, notably TNF-cx, and IFN-y [12, 13] . When examined by electron microscopy, livers from Con A-treated mice demonstrated severe cellular damage as early as 4-6 hr after Con A administration [11] , whereas histologic changes could be demonstrated by light microscopy only 24 hours after the inoculation of Con A [13] . A recent study have suggested that Con A-induced apoptosis of liver cells is dominantly mediated by a perforin-dependent pathway through ICAM-l/ILFA-1 interaction and not through the Fas ligand pathway [14] . This mouse model of acute liver damage, might be useful for the investigation of the pathogenesis and the efficacy of experimental treatment modalities in chronic hepatic inflammation and in some cholestatic liver diseases as well, since similar processes take place during an immune response to chronic liver insult. T-cells were purified from spleens of BALB/c mice, left untreated (control), or activated with Con A, in the presence or absence of the nonpeptidic mimetics of RGD and RGE. One of three experiments, which yielded essentially the same results (SD < 13%). Adapted from Ref. [15] .
PREVENTION OF CON A-INDUCED HEPATITIS BY SYNTHETIC RGD ANALOGUES
Inhibition of liver enzymes elevation BALB/c mice were injected intravenously with 10 mg/kg Con A, and treated daily for 5 days prior to Con A inoculation, with either 500 jg/mouse of one of the RGD analogues SF-6,5 or NS-11, or the RGE analogue SF-6,6 (as a control group). In a previous study, the RGD analogue SF-6,5 inhibited delayed type hypersensitivity reaction in mice, with the best results obtained when the mice were injected daily for 5 days prior to the experiment [8] . As expected, the control RGE mimetic, SF-6,6, which has a 12-atom spacing chain between the two ionic functional groups, and therefore lacks integrin specificity, did not prevent liver damage induced by Con A inoculation. In contrast, the RGD mimetic SF-6,5 effectively decreased the high serum levels of both liver enzymes tested (Table 3 ; Ref. [15] ). When SF-6,5 was administered at a single i.p. dose of 500 jg/mouse 1 hour prior to Con A injection or orally (at 500 jg/mouse) for 5 days prior to the induction of hepatitis, the increase in serum levels of liver enzymes was inhibited by only -50 percent (data not shown). Based on the above data, we concluded that pre-treatment of the animals with the RGD mimetics for 5 days was more effective in the prevention of T-cell-dependent immune-mediated hepatitis in mice. Mean + SEM; n = 6; **p < .01 compared to Con A alone.
Serum levels of liver enzymes were measured 24 hr after Con A (10 mg/kg, i.v.) administration. Similar results were obtained when liver enzymes were assessed 6 h after the administration of Con A (not shown). The RGE and RGD mimetics were administered i.p. daily for 5 days prior to Con A administration. Adapted from Refs. [15, 16] . RGD analogue (500 jg/mouse) was administered daily for 5 days prior to and on the day of Con A inoculation. Serum levels of TNF-a were significantly decreased 2 and 6 hr after Con A injection in the SF-6,5 pretreated mice compared to control mice that received only Con A. Adapted from Ref [16] . INHIBITION OF TNF-a RELEASE BY SF-6,5 As reported recently, Con A-induced hepatic injury is mediated by cytokines such as TNF-a, IL-2 and IFN-y [11] [12] [13] . The increase in serum levels of TNF-a in response to Con A, was inhibited by the RGD mimetic SF-6,5 (Figure 2 ; Ref. [16] ). Thus, the prevention of Con A-induced liver injury by the RGD mimetic is also associated with inhibition of TNFa release.
Effects of the RGD mimetic SF-6,5 on liver histology Livers of control rats, treated with Con A only or with the inactive RGE analogue SF-6,6, demonstrated areas of intralobular necrosis and inflammatory cell infiltrates around the central veins and the portal tracts. Inflammatory infiltrates consisted mainly of mononuclear cells, many of which were positively stained by anti-CD4 by immunohistochemistry. Compatible with previous studies, these results further establish the major role of the CD4+ T-cell sub population in the etiology and pathogenesis of Con A-induced hepatitis [11] . As expected, the control RGE mimetic SF-6,6 did not prevent the apparent liver inflammation. In contrast, in mice treated by the RGD analogue SF-6,5 liver damage was minimal: no intralobular necrosis or significant inflammatory infiltration could be demonstrated by light microscopy ( Table 4) . Inhibition of liver damage by soluble receptor Hepatic injury in Con A-induced hepatitis is mediated primarily by TNF-a, and this damage could be prevented by the use of polyclonal TNF-oc antiserum [ 13] . Recombinant soluble TNF receptors (sTNF-R) have been developed and can be used to neutralize TNFa in vivo [5] . Therefore, sTNF-R (p55 recombinant human soluble TNF receptor, Interpharm, Israel), was administered intravenously, 1 hour prior to Con A injection in order to prevent liver damage and to confirm the major role of TNF-y in Con A-induced hepatitis.
sTNF-R, at a molar ratio of 1: 103 or 1: 104 to TNF-a (1 or 10 ,ug/mouse respectively, based on TNF-a serum level measured 2 hr after Con A inoculation), had no effect on the release of aminotransferases (Table 5) . However, sTNF-R, at a molar ratio of 1: 105 to TNF-a (100 jig/mouse), effectively inhibited the Con A-induced elevation of hepatic enzymes and of TNF-a (Table 5, Figure 3) . Thus, in vivo administration of sTNF-R, that inhibits the increase of serum TNF levels in response to Con A, appears to decrease the biochemical manifestations of experimentally-induced liver damage.
The histopathologic manifestations of liver damage were also prevented by the administration of the sTNFR at a dose of 100 ,ug/mouse (Table 4) . Apoptosis of liver cells Figure 3 . Effect of soluble receptor of TNF on serum levels of TNF-a in mice. Soluble receptor of TNF was administered i.v. at a dose of 100 gg/mouse 1 hr prior to Con A administration. Serum levels of TNF-a were measured 2-24 hr after the administration of 10 mg/kg Con A, and were significantly decreased 2 and 6 hr after Con A injection in the sTNF-R pretreated mice, compared to control mice that received only Con A. Lower doses of sTNF-R (1 and 10 rg/mouse) were not effective in preventing Con A-induced hepatitis. Adapted from Ref. [16] .
is an early event in Con A-induced hepatitis, that could be demonstrated histopathologically as early as 3 hr after the inoculation of Con A [12] . In liver sections taken from rats treated with sTNF-R, which were examined 2 and 6 hr after the injection of Con A, apoptosis of liver cells was not detected.
INHIBITION OF HEPATIC FIBROSIS BY THE NON-PEPTIDIC MIMETIC OF RGD, SF-6,5
A chronic insult induces a prolonged inflammatory process that may lead to the development of liver fibrosis. The process of fibrosis appears to result from complex interactions between extracellular matrix macromolecules, hepatic stellate cells, cytokines and growth factors. Secreted soluble cytokines, probably link the inflammatory and reparative phase of liver cirrhosis, by activating hepatic stellate cells (HSC) cells. Upon activation, HSC proliferate and initiate the fibrogenic process by depositing matrix components, such as collagen, glycoproteins (e.g., laminin) and proteoglycans in the space of Disse, and as the chronic liver insult persists it eventually progresses to nodule formation and cirrhosis [17] . Transforming growth factor (TGF) B contributes to the fibrotic process by modulating matrix formation by inducing the synthesis of fibronectin, laminin, collagen I, proteoglycans and tissue inhibitors of metalloproteinases [18, 19] . TGFB also enhances Bi integrin expression in a manner that increases cellular adhesion to the matrix proteins [20] . Hence, the management of hepatic fibrosis should involve, in addition to suppressing or eliminating the causative agents of chronic hepatic inflammation, a specific action on the ECM.
RGD ANALOGUES AND THE INHIBITION OF LIVER FIBROSIS IN RATS
Administration of thioacetamide and the RGD and RGE analogues Liver fibrosis was induced by the administration of thioacetamide (TAA) 0.03 percent (Sigma Chemical Co., St. Louis, MO) in the drinking water for 12 weeks. The synthesized SF-6,5 and SF-6,6 were administered i.p. 5 days a week. Rats were treated as follows: One group received TAA and i.p. injections of 0.9 percent NaCl 5 days a week for 12 weeks (cirrhotic controls for the RGD-treated groups). Other groups received TAA orally and either i.p. SF-6,5 (100 jg/day), SF-6,5 (500 jig/day), SF-6,6 (500 ,ug/day) the RGD-containing peptide (GRGDSPK), (Sigma Chemical Co., St. Louis, MO) 500 jg/day for 5 days a week. The control groups consisted of one that received tap water without TAA for 12 weeks (normal controls) and a group of rats that received only SF-6,5 for 12 weeks to look for adverse effects. Liver histopathology Liver sections were processed for light microscopy including staining the sections with hematoxylin and eosin, and Masson trichrome. The degree of inflammation and fibrosis was expressed as the mean of 10 different fields in each slide that had been classified on a scale of 0-3 according to Muller et al. [21] .
The administration of the RGD-containing peptide (GRGDSPK) or the RGE analogue SF-6,6 for 12 weeks did not prevent the development of liver cirrhosis (Table 6) in TAA-treated rats. The livers of rats that received TAA and a low dose (100 jg/day) of the RGD analogue for 12 weeks showed cirrhotic lesions similar to the group treated with TAA alone for 12 weeks (Table 6; Ref 22 ). Thus, a low dose of SF-6,5 was not effective in preventing liver cirrhosis. In contrast, the livers of rats that received TAA and a higher dose (500 jig/day) of SF-6,5 for 12 weeks showed slight portal and peri-portal inflammation with mild bridging fibrosis, but no cirrhotic nodules or passive fibrotic septa [22] . Quantitative analysis of liverfibrosis Hepatic fibrosis was quantitated by computerized imaging morphometry with a computerized video-imaging system (Biological Detection System, Pittsburgh, PA), as previously described [23] . The mean integrated optical density values of the histologic slides of the TAA-treated group were significantly higher than those of the TAA plus SF-6,5 (500 ,ug/day) and the control groups ( Figure 4A ). This quantitative morphometric method confirmed the results of the histopathologic scoring.
Spleen weights
An indirect measure of portal hypertension was obtained by measuring the weights of the rats spleens when treatment was ended. After 12 weeks, the mean spleen weight of rats receiving TAA daily was about 80 percent higher than those receiving normal tap water and injections of 0.9 percent NaCl ( Figure 4B ). The mean spleen weight of rats that received SF-6,5 (500 jig/day) in addition to TAA for 12 weeks was only about 30 Moreover, the elevation of serum TNF-a, was also inhibited by pretreatment of mice with either the RGD mimetic or sTNF-R, suggesting that either neutralization of serum TNFa, or inhibition of the interaction between T-lymphocytes and the ECM effectively prevent the cytokine response, and might be one of the mechanisms by which these compounds protect against Con A hepatitis. The inhibition of Con A hepatitis by sTNF-R is consistent with previous studies that suggested a pivotal role for TNF-a, in the induction of Con A-induced liver injury in mice [1 1-13] , and confirm that neutralization of endogenous TNF-a, by sTNF-R, can prevent liver injury in this model.
The synthetic RGD analogue SF-6,5 was also effective in alleviating hepatic fibrosis induced by the hepatotoxin TAA. In this rat model, liver cirrhosis results from the inhibition of respiratory metabolism and enzymatic activity within the nuclei of liver cells by reactive oxygen species rather than by a direct stimulation of immune cells (although immune cells are involved in the induction of cirrhosis by TAA) [24] .
During the process of hepatic fibrogenesis, HSC, which in chronically injured liver are activated by cytokines such as platelet derived growth factor [25] , TGF31 [26] and other factors, acquire a myofibroblast-like phenotype, are the major source of matrix components in both normal and fibrotic livers [27] . Normal liver subendothelial space is known to lack a true basement membrane, although the presence of ECM glycoproteins typical of basement membrane such as collagens, laminin and fibronectin have been described [28] . Cell-matrix interaction may be important in HSC activation [29] . Recent studies have shown that the interactions of epithelial cells with ECM components such as fibronectin via integrins play an important role in wound healing [30] , fibrosis [31] and hepatic regeneration. One of the earliest detectable changes in the ECM of the insulted liver is an increase in total FN [32] . In human tenon's capsule fibroblasts adhesion to FN is an RGD-dependent process [33] . inflammatory cells and the ECM by RGD mimetics was proposed, since the RGD-dependent interaction of resting T-cells and macrophages with ECM components results in secretion of TNF-ax and fibroblast growth factor. Moreover, when ECM is physically damaged, cytokine secretion is enhanced [35] . As shown in mice, the administration of SF-6,5 effectively inhibited the release of TNF-a in response to Con A administration. During inflammation, proteases released by lymphocytes can degrade normal ECM components, and in particular FN, to biologically active peptides that are chemoattractants for fibroblasts [36] . During fibrogenesis, these chemoattracted myofibroblasts complete the reparative phase by depositing ECM constituents. Therefore, inhibition of myofibroblast accumulation or activation may alleviate fibrogenesis [34] .
It has been reported that RGD-containing peptides can dramatically signal the secretion of proteases such as collagenase and stromelysin from cultured synovial fibroblasts [37] . Thus, enhancement of collagen degradation due to increased production or activity of matrix metalloproteinases may also play a role in the inhibition of hepatic fibrosis by RGD analogues, and this possibility should be tested in future studies.
Thus, nonpeptidic mimetics of cell adhesion motifs can pharmacologically affect pathological processes involved in hepatic fibrosis. Although the mechanism(s) by which the RGD analogue induced the antifibrotic effect was not elucidated in our studies, the processes that may be affected by these mimetics during chronic liver injury include immune cell migration, cytokine release, activation and adhesion of activated HSC to ECM or enhancement of collagen degradation due to increased production or activity of matrix metalloproteinases.
Thus, nonpeptidic analogues of the versatile ECM adhesion epitopes may be effective in preventing chronic hepatic inflammation and fibrosis, and should be considered therapeutically to inhibit pathological conditions in the liver. In preliminary studies, no apparent side effects attributable to SF-6,5 were observed in rats that received only the RGD mimetic for 12 weeks. However, further efficacy and toxicity studies are indicated before considering these compounds therapeutically for patients with liver diseases.
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